Asian Journal of Psychiatry
2026
Hemant Bhargav, Urvakhsh Meherwan Mehta, Ashish Kumar et al.
This paper explores pranayama, the ancient yogic practice of breath control, as a promising natural method of neuromodulation. Pranayama aims to regulate the flow of prana (life force) to enhance mental clarity, emotional balance, and physiological resilience. We synthesize evidence from clinical, neuroimaging, and psychophysiological studies, illustrating how various pranayama techniques -...
Scientific Data
June 5, 2025
Subha Subramanian, Travis Rick Renau, Demetrius Perry et al.
4 citations
Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to...
Nature
August 1, 2024
Joshua S. Siegel, Subha Subramanian, Demetrius Perry et al.
241 citations
A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persistent therapeutic effects in human clinical trials1-4. In animal models, psilocybin induces neuroplasticity in cortex and hippocampus5-8. It remains unclear how human brain network changes relate to subjective and lasting effects of psychedelics. Here...
Biological Psychiatry
April 29, 2024
Joshua S. Siegel, Subha Subramanian, Nico U.f. Dosenbach et al.
14 citations
1 Summary The relationship between the acute effects of psychedelics and their persisting neurobiological and psychological effects is poorly understood. Here, we tracked brain changes with longitudinal precision functional mapping in healthy adults before, during, and for up to 3 weeks after oral psilocybin and methylphenidate (17 MRI visits per participant) and again 6+ months later....
Journal of Neurological Sciences
2022
Subha Subramanian, S. Haroutounian, Ben J Palanca et al.
58 citations
Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic...
Mindfulness
October 5, 2021
Heather J. Brooks, H. Oughli, Lojine Y. Kamel et al.
Individuals with subjective memory complaints and symptoms of depression and/or anxiety are at high risk for further cognitive decline, and possible progression to dementia. Low-burden interventions to help slow or prevent cognitive decline in this high-risk group are needed. The objective of this study is to assess the feasibility of combining Mindfulness-Based Stress Reduction (MBSR) with...
October 23, 2018
Bashkim Kadriu, Subha Subramanian, Z. Deng et al.
preprint
Major depressive disorder (MDD) is a highly prevalent and debilitating illness and closely linked to suicide risk. Currently available antidepressants take weeks to work and have low remission rates; indeed, about a third of individuals with MDD fail to fully remit in response to these agents. Novel therapies that target the glutamatergic system—such as ketamine—offer rapid antidepressant...